SQUAWK/NEWS
Account
Theme
Account
Menu
Live News MNA ARTICLE M impact

OBI Pharma Gets $30M Upfront in Novartis ADC Collaboration

OBI Pharma will receive $30 million upfront and is eligible for development, regulatory and commercial milestones that could bring total deal value to more than $2 billion, plus tiered royalties.

4174

OBI Pharma will receive $30M upfront under an ADC collaboration with Novartis and is eligible for development, regulatory and commercial milestones bringing total potential deal value to over $2B, plus tiered royalties. No prior-period comparison was provided.Material DetailsContext by AI AnalystTh…

Related stories